CRISPR

CRISPR3-surf1

ID

ZDB-CRISPR-231108-15

Name

CRISPR3-surf1

Previous Names

None

Target

surf1 (1)

Sequence

5' - CACTCTACAGGCAGTGGGATTGG - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Genome Build: GRCz11Chromosome: 5

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
cri2	surf1

Expression

Gene expression in Wild Types + CRISPR3-surf1

No data available

Phenotype

Phenotype resulting from CRISPR3-surf1

No data available

Phenotype of all Fish created by or utilizing CRISPR3-surf1

Phenotype	Fish	Conditions	Figures
swim bladder decreased size, abnormal	surf1^cri2/cri2	standard conditions	Fig. 4 , Fig. 5 from Sharma et al., 2023
brain opaque, ameliorated	surf1^cri2/cri2	chemical treatment by environment: N-acetyl-L-cysteine, chemical treatment by environment: sodium azide	Fig. 6 from Haroon et al., 2023
brain transparent, abnormal	surf1^cri2/cri2	chemical treatment by environment: sodium azide	Fig. 6 from Haroon et al., 2023
swimming behavior decreased process quality, exacerbated	surf1^cri2/cri2	chemical treatment by environment: sodium azide	Fig. 5 from Haroon et al., 2023
swimming behavior decreased process quality, abnormal	surf1^cri2/cri2	standard conditions	Fig. 3, Fig. 5 from Haroon et al., 2023
heart contraction decreased process quality, exacerbated	surf1^cri2/cri2	chemical treatment by environment: sodium azide	Fig. 5 from Haroon et al., 2023
glutathione metabolic process decreased process quality, abnormal	surf1^cri2/cri2	chemical treatment by environment: sodium azide	Fig. 7 from Haroon et al., 2023
heart contraction process quality, ameliorated	surf1^cri2/cri2	chemical treatment by environment: N-acetyl-L-cysteine, chemical treatment by environment: sodium azide	Fig. 6 from Haroon et al., 2023
liver decreased size, abnormal	surf1^cri2/cri2	standard conditions	Fig. 4 , Fig. 5 from Sharma et al., 2023
thigmotaxis process quality, ameliorated	surf1^cri2/cri2	chemical treatment by environment: N-acetyl-L-cysteine, chemical treatment by environment: sodium azide	Fig. 6 from Haroon et al., 2023
reactive oxygen species biosynthetic process rate, ameliorated	surf1^cri2/cri2	chemical treatment by environment: N-acetyl-L-cysteine, chemical treatment by environment: sodium azide	Fig. 7 from Haroon et al., 2023
thigmotaxis decreased process quality, exacerbated	surf1^cri2/cri2	chemical treatment by environment: sodium azide	Fig. 5 from Haroon et al., 2023
heart decreased size, abnormal	surf1^cri2/cri2	standard conditions	Fig. 4 , Fig. 5 from Sharma et al., 2023
cranial nerve II decreased size, abnormal	surf1^cri2/cri2	standard conditions	Fig. 4 , Fig. 5 from Sharma et al., 2023
eye decreased size, abnormal	surf1^cri2/cri2	standard conditions	Fig. 4 , Fig. 5 from Sharma et al., 2023
regulation of cytochrome-c oxidase activity decreased process quality, abnormal	surf1^cri2/cri2	standard conditions	Fig. 2 from Haroon et al., 2023
inner ear increased size, abnormal	surf1^cri2/cri2	standard conditions	Fig. 4 , Fig. 5 from Sharma et al., 2023
regulation of cytochrome-c oxidase activity decreased process quality, abnormal	surf1^cri2/cri2	chemical treatment by environment: cysteamine bitartrate, chemical treatment by environment: sodium azide	Fig. 7 from Haroon et al., 2023
reactive oxygen species biosynthetic process rate, ameliorated	surf1^cri2/cri2	chemical treatment by environment: cysteamine bitartrate, chemical treatment by environment: sodium azide	Fig. 7 from Haroon et al., 2023
whole organism Ab4-cox4 labeling decreased amount, abnormal	surf1^cri2/cri2	standard conditions	Fig. 2 from Haroon et al., 2023
thigmotaxis decreased process quality, abnormal	surf1^cri2/cri2	standard conditions	Fig. 5 from Haroon et al., 2023
heart contraction decreased process quality, abnormal	surf1^cri2/cri2	standard conditions	Fig. 5 from Haroon et al., 2023
swimming behavior decreased process quality, abnormal	surf1^cri2/cri2	chemical treatment by environment: sodium azide	Fig. 6 from Haroon et al., 2023
lactate biosynthetic process increased rate, abnormal	surf1^cri2/cri2	chemical treatment by environment: sodium azide	Fig. 7 from Haroon et al., 2023
lactate biosynthetic process increased rate, exacerbated	surf1^cri2/cri2	chemical treatment by environment: cysteamine bitartrate, chemical treatment by environment: sodium azide	Fig. 7 from Haroon et al., 2023
whole organism decreased weight, abnormal	surf1^cri2/cri2	standard conditions	Fig. 6 from Sharma et al., 2023
kidney decreased size, abnormal	surf1^cri2/cri2	standard conditions	Fig. 4 , Fig. 5 from Sharma et al., 2023
brain transparent, exacerbated	surf1^cri2/cri2	chemical treatment by environment: sodium azide	Fig. 5 from Haroon et al., 2023
brain decreased size, abnormal	surf1^cri2/cri2	standard conditions	Fig. 4 from Sharma et al., 2023
heart contraction decreased process quality, abnormal	surf1^cri2/cri2	chemical treatment by environment: sodium azide	Fig. 6 from Haroon et al., 2023
spinal cord decreased size, abnormal	surf1^cri2/cri2	standard conditions	Fig. 4 , Fig. 5 from Sharma et al., 2023
swimming behavior process quality, ameliorated	surf1^cri2/cri2	chemical treatment by environment: cysteamine bitartrate, chemical treatment by environment: sodium azide	Fig. 6 from Haroon et al., 2023
glutathione metabolic process process quality, ameliorated	surf1^cri2/cri2	chemical treatment by environment: cysteamine bitartrate, chemical treatment by environment: sodium azide	Fig. 7 from Haroon et al., 2023
thigmotaxis decreased process quality, abnormal	surf1^cri2/cri2	chemical treatment by environment: sodium azide	Fig. 6 from Haroon et al., 2023
brain opaque, ameliorated	surf1^cri2/cri2	chemical treatment by environment: cysteamine bitartrate, chemical treatment by environment: sodium azide	Fig. 6 from Haroon et al., 2023
swimming behavior process quality, ameliorated	surf1^cri2/cri2	chemical treatment by environment: N-acetyl-L-cysteine, chemical treatment by environment: sodium azide	Fig. 6 from Haroon et al., 2023
thigmotaxis process quality, ameliorated	surf1^cri2/cri2	chemical treatment by environment: cysteamine bitartrate, chemical treatment by environment: sodium azide	Fig. 6 from Haroon et al., 2023
brain transparent, abnormal	surf1^cri2/cri2	standard conditions	Fig. 5 from Haroon et al., 2023
heart contraction process quality, ameliorated	surf1^cri2/cri2	chemical treatment by environment: cysteamine bitartrate, chemical treatment by environment: sodium azide	Fig. 6 from Haroon et al., 2023
reactive oxygen species biosynthetic process increased rate, abnormal	surf1^cri2/cri2	chemical treatment by environment: sodium azide	Fig. 7 from Haroon et al., 2023
brain increased size, abnormal	surf1^cri2/cri2	standard conditions	Fig. 5 from Sharma et al., 2023

Citations

Include unpublished citations

Haroon, S., Yoon, H., Seiler, C., Osei-Frimpong, B., He, J., Nair, R.M., Mathew, N.D., Burg, L., Kose, M., Venkata, C., Anderson, V.E., Nakamaru-Ogiso, E., Falk, M.J. (2023) N-Acetylcysteine and cysteamine bitartrate prevent azide-induced neuromuscular decompensation by restoring glutathione balance in two novel surf1-/- zebrafish deletion models of Leigh syndrome. Human molecular genetics. 32(12):1988-2004

1 - 1 of 1

Show